ALKBC logo

ALK-Abelló BATS-CHIXE:ALKBC Stock Report

Last Price

DKK 164.90

Market Cap

DKK 33.8b

7D

0%

1Y

n/a

Updated

18 Dec, 2024

Data

Company Financials +

ALK-Abelló A/S

BATS-CHIXE:ALKBC Stock Report

Market Cap: DKK 33.8b

ALKBC Stock Overview

Operates as an allergy solutions company in Europe, North America, and internationally. More details

ALKBC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

ALK-Abelló A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for ALK-Abelló
Historical stock prices
Current Share PriceDKK 164.90
52 Week HighDKK 165.60
52 Week LowDKK 100.40
Beta0.62
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-1.55%
5 Year Change100.12%
Change since IPO562.25%

Recent News & Updates

Recent updates

Shareholder Returns

ALKBCGB PharmaceuticalsGB Market
7D0%-1.5%-1.5%
1Yn/a-2.8%3.5%

Return vs Industry: Insufficient data to determine how ALKBC performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ALKBC performed against the UK Market.

Price Volatility

Is ALKBC's price volatile compared to industry and market?
ALKBC volatility
ALKBC Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ALKBC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine ALKBC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,795Peter Hallingwww.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

ALK-Abelló A/S Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
ALKBC fundamental statistics
Market capDKK 33.84b
Earnings (TTM)DKK 785.00m
Revenue (TTM)DKK 5.38b

43.1x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALKBC income statement (TTM)
RevenueDKK 5.38b
Cost of RevenueDKK 1.94b
Gross ProfitDKK 3.44b
Other ExpensesDKK 2.66b
EarningsDKK 785.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.55
Gross Margin63.96%
Net Profit Margin14.58%
Debt/Equity Ratio3.7%

How did ALKBC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 03:55
End of Day Share Price 2024/10/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALK-Abelló A/S is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
Alexandru CogutBryan Garnier & Co
Jesper IlsoeCarnegie Investment Bank AB